https://www.selleckchem.com/pr....oducts/5-n-ethylcarb
77% vs 2.92%, P = 0.04). HER2 amplification was an independent prognostic factor for worse disease-free survival (DFS) (HR = 2.53, 95% CI 1.21-5.30, P = 0.014). Conclusion The prevalence of HER2 amplification and BRAF V600E mutation in stage I-III CRC patients in Chinese was 6% and 4%, respectively, and HER2 amplification appeared to be associated with a worse DFS. More comprehensive molecular classification and survival analysis are needed to validate our findings. © 2020 Zhang et al.Purpose The development of int
Curtir
Comentario
Compartilhar
